van Ginkel RJ - Search Results

1

PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.

Kole AC, Pruim J, Nieweg OE, van Ginkel RJ, Hoekstra HJ, Schraffordt Koops H, Vaalburg W. Kole AC, et al. Among authors: van ginkel rj. J Nucl Med. 1997 Feb;38(2):191-5. J Nucl Med. 1997. PMID: 9025733 Free article.

2

Schut AW, Timbergen MJM, Nasserinejad K, van Dalen T, van Houdt WJ, Bonenkamp JJ, Sleijfer S, Grünhagen DJ, Verhoef C, Husson O; Dutch Grafiti Group. Schut AW, et al. Ann Surg. 2023 Jun 1;277(6):877-883. doi: 10.1097/SLA.0000000000005795. Epub 2023 Jan 19. Ann Surg. 2023. PMID: 36727954 Free PMC article.

3

Hyperthermic isolated regional perfusion with cisplatin in the local treatment of spontaneous canine osteosarcoma: assessment of short-term effects.

Van Ginkel RJ, Hoekstra HJ, Meutstege FJ, Oosterhuis JW, Uges DR, Schraffordt Koops H. Van Ginkel RJ, et al. J Surg Oncol. 1995 Jul;59(3):169-76. doi: 10.1002/jso.2930590307. J Surg Oncol. 1995. PMID: 7609523

4

Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan.

van Ginkel RJ, Hoekstra HJ, Eggermont AM, Pras E, Koops HS. van Ginkel RJ, et al. Arch Surg. 1996 Jun;131(6):672-4. doi: 10.1001/archsurg.1996.01430180098022. Arch Surg. 1996. PMID: 8645079

5

Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.

Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, Koops HS, Vaalburg W. Nieweg OE, et al. Among authors: van ginkel rj. J Nucl Med. 1996 Feb;37(2):257-61. J Nucl Med. 1996. PMID: 8667056 Free article.

6

FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.

van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE, Molenaar WM, Paans AM, Willemsen AT, Vaalburg W, Koops HS. van Ginkel RJ, et al. J Nucl Med. 1996 Jun;37(6):984-90. J Nucl Med. 1996. PMID: 8683328 Free article.

7

High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.

Zwaveling JH, Maring JK, Clarke FL, van Ginkel RJ, Limburg PC, Hoekstra HJ, Koops HS, Girbes AR. Zwaveling JH, et al. Among authors: van ginkel rj. Crit Care Med. 1996 May;24(5):765-70. doi: 10.1097/00003246-199605000-00007. Crit Care Med. 1996. PMID: 8706451 Clinical Trial.

8

Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.

Zwaveling JH, Maring JK, Mulder AB, Bom VJ, van Ginkel RJ, Schraffordt Koops H, Girbes AR, Hoekstra HJ, van der Meer J. Zwaveling JH, et al. Among authors: van der meer j, van ginkel rj. Cancer Res. 1996 Sep 1;56(17):3948-53. Cancer Res. 1996. PMID: 8752162 Clinical Trial.

9

Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone.

van Ginkel RJ, Schraffordt Koops H, de Vries EG, Molenaar WM, Uges DR, Hoekstra HJ. van Ginkel RJ, et al. Eur J Surg Oncol. 1996 Oct;22(5):528-31. doi: 10.1016/s0748-7983(96)93114-5. Eur J Surg Oncol. 1996. PMID: 8903498

10

Role of nitric oxide in recombinant tumor necrosis factor-alpha-induced circulatory shock: a study in patients treated for cancer with isolated limb perfusion.

Zwaveling JH, Maring JK, Moshage H, van Ginkel RJ, Hoekstra HJ, Schraffordt Koops H, Donse IF, Girbes AR. Zwaveling JH, et al. Among authors: van ginkel rj. Crit Care Med. 1996 Nov;24(11):1806-10. doi: 10.1097/00003246-199611000-00008. Crit Care Med. 1996. PMID: 8917029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters